Interim Chief Executive Officer and President
Vice President of Finance and Chief Accounting Officer
Kevin has been Vice President of Finance and Chief Accounting Officer since 2014. Previously, he was Vice President, Finance and Administration for Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics. Prior to joining Avaxia, he served from 2009 to 2013 at various biotechnology and medical device companies in interim Vice President of Finance and Controller roles. From 2005 to 2009, Kevin was the Corporate Controller and Principal Accounting Officer of NitroMed, a publicly traded cardiovascular-focused pharmaceutical company. Kevin earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. He is a certified public accountant in the Commonwealth of Massachusetts.
Chairman of the Board
Wael has served as Enumeral’s Chairman since September 2016, and served as the company’s President and Chief Executive Officer from September 2016 until June 2017. Wael has over than two decades of senior executive and business development experience in the life sciences industry. From 2001 to 2014, he held positions of increasing responsibility at Forest Laboratories, Inc., culminating as Corporate Vice President, Global Business Development. In that role, he was responsible for business development and alliance management, including the identification, assessment and negotiation of multiple business opportunities. Wael helped build and manage a broad network of partnerships at Forest, and upon Forest’s acquisition by Actavis, he also assisted with the integration of the two companies. Wael was subsequently engaged in a number of entrepreneurial ventures, including helping to launch Valentine & Cautreels, Inc., a start-up company focusing on improving healthcare outcomes and reducing the total cost of care. He continues to serve on Valentine & Cautreels’ advisory board. Prior to Forest, Wael served in positions of increasing responsibility at Schering-Plough and Novartis in the fields of sales, marketing, and new product development. Wael holds a B.S. in biology from the American University of Beirut, and an M.B.A. from Concordia University.
Chairman, Scientific Adivsory Board, and Co-founder, Enumeral
Chief Executive Officer, BiologicB
Dr. Buckland has been a member of our Board of Directors since 2009. His career in the pharmaceutical industry includes leadership of Merck’s world class Bioprocess Research and Development Group which saw the market launch of major biological products, including Gardasil®, Rotateq®, and Zostavax®. Dr. Buckland has been the Chief Executive Officer of BiologicB, a consulting firm working with biotechnology and vaccine products, since 2009. He is the recipient of numerous awards, among them the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award as a member of the team that received the Vaccine Award for Gardasil in 2007, the Marvin Johnson award by ACS for lifetime contribution to Biotechnology in 2008, and the PhRMA Discoverer of the Year for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen) in 2009. Dr. Buckland has chaired multiple International Conferences related to bioprocess research and development and vaccine technology and is an author on over 70 papers. He has been a Visiting Professor at University College London since 1995. Dr. Buckland earned his Ph.D. in biochemical engineering at University College London. He is a member of Enumeral's Compensation Committee and is the chairperson of the Nominating and Governance Committee.
Principal, Hedge Capital Partners
Mr. Rothstein has been a member of our Board of Directors since 2013. He has over 30 years of experience in the financial services industry and is currently Principal of Hedge Capital Partners, an investment vehicle for venture capital, portfolio management and asset management. From 2011 to 2014, he was a principal of Healthcare Recovery Services, which serves financial aspects and enhances revenue cycles of hospitals and other healthcare service enterprises. From 2010 to 2011, Mr. Rothstein was head of trading at Centurion Partners. He is also the owner of Shizoom, a business funding company. Prior to Hedge Capital Partners, he was Senior Vice President and co-head of NASDAQ trading at Fahnestock & Company (now Oppenheimer & Company). Mr. Rothstein started his career at Shearson Loeb Rhoades, handling arbitrage lines for domestic and international customers. He served as a member of the National Nanotechnology Business Alliance and the New York Nanotechnology Business Alliance advisory boards and the Dean’s Council of the Graduate School of SUNY Stonybrook. Mr. Rothstein graduated as a Benjamin Franklin Scholar from the University of Pennsylvania.
President, Chief Executive Officer and Director, Lycera
Mr. Sekhri has been a member of our Board of Directors since 2014. He is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies. He is currently President and Chief Executive Officer of Lycera, and he also serves on its board of directors. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, and before that, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Operations Group at TPG Biotech, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri was founder, President and Chief Executive Officer of Cerimon Pharmaceuticals, and before Cerimon, he was President and Chief Business Officer of Ariad Pharmaceuticals. He also held senior positions at Novartis, including Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri is also a director of Veeva Systems and has served as a director on numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as a board advisor to IMS Health. He serves on the Board of Trustees for the non-profit Cancer Research Institute and on the Industry Advisory Boards of the Michael J. Fox Foundation, the TB Alliance and the Tectonic Theatre Project. Mr. Sekhri received a B.S. from the University of Maryland and completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine. He is a member of Enumeral's Audit Committee and Nominating and Governance Committee, as well as the chairperson of the Compensation Committee.
Former Chief Financial Officer, OSI Pharmaceuticals
Mr. Van Nostrand has been a member of our Board of Directors since 2014. He is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. During his tenure with OSI Pharmaceuticals, he had financial responsibility for all of its significant operations and was instrumental in development of strategy, budgeting and forecasting, negotiation and closing of several major corporate collaborations, and SEC reporting. During his tenure, Mr. Van Nostrand led the OSI financial team in raising over $1.4 billion in equity and debt during a time of high growth as OSI transitioned from an early-stage biotechnology company to a multi-billion dollar, commercial-stage organization. Prior to joining OSI, he was a manager at Touche Ross & Co (currently Deloitte). Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York. He is the former Chairman, and currently serves on the board, of NYBio (formerly the New York Biotechnology Association) and also serves on the Foundation Board of Farmingdale University. Mr. Van Nostrand received a B.S. in accounting from Long Island University and studied management at The Wharton School of the University of Pennsylvania. He is a Certified Public Accountant. He is a member of Enumeral's Audit Committee, Compensation Committee, and Nominating and Governance Committee.